Literature DB >> 8100126

Establishment and characterization of multidrug-resistant human osteosarcoma cell lines.

M Serra1, K Scotlandi, M C Manara, D Maurici, P L Lollini, C De Giovanni, G Toffoli, N Baldini.   

Abstract

Multidrug resistant variants of two human osteosarcoma cell lines (U-2 OS and Saos-2) were selected by continuous exposure to doxorubicin. The in vitro and in vivo growth characteristics of these sublines as well as the expression of osteoblastic markers and of some surface antigens were analyzed. Resistant variants showed a higher doubling time and a lower cloning efficiency, and a lower metastatic ability after i.v. injection than corresponding parental cell lines. All the sublines showed overexpression of p-glycoprotein (referred to as p170). The level of expression of this protein in the different cell lines was directly related to the degree of resistance as shown by the in vitro sensitivity to doxorubicin and other multidrug-related drugs. In sublines showing the highest levels of resistance (over 300-fold), p170 overexpression was associated with mdr 1 gene amplification. These are the first multidrug resistant human osteosarcoma cell lines ever reported. They may be used as a model for further investigations into the mechanisms of drug resistance in osteosarcoma and as a standard for the assessment of chemosensitivity in clinical samples.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100126

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  26 in total

1.  Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.

Authors:  B Liu; E Staren; T Iwamura; H Appert; J Howard
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Invariant NKT cells increase drug-induced osteosarcoma cell death.

Authors:  S Fallarini; T Paoletti; N Orsi Battaglini; G Lombardi
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis.

Authors:  Hue H Luu; Quan Kang; Jong Kyung Park; Weike Si; Qing Luo; Wei Jiang; Hong Yin; Anthony G Montag; Michael A Simon; Terrance D Peabody; Rex C Haydon; Carrie W Rinker-Schaeffer; Tong-Chuan He
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities.

Authors:  M Serra; K Scotlandi; M C Manara; D Maurici; S Benini; M Sarti; G Nini; G Barbanti-Brodano; N Baldini
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

5.  P53 Overexpression as an Indicator of Overall Survival and Response to Treatment in Osteosarcomas.

Authors:  Zsuzsa Pápai; Christina N Féja; Eid N Hanna; Mariann Sztán; Edit Oláh; Miklós Szendrôi
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

6.  Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells.

Authors:  N Zini; A Ognibene; A Bavelloni; S Santi; P Sabatelli; N Baldini; K Scotlandi; M Serra; N M Maraldi
Journal:  Histochem Cell Biol       Date:  1996-11       Impact factor: 4.304

7.  Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.

Authors:  Valeria Sero; Elisa Tavanti; Serena Vella; Claudia Maria Hattinger; Marilù Fanelli; Francesca Michelacci; Rogier Versteeg; Barbara Valsasina; Beth Gudeman; Piero Picci; Massimo Serra
Journal:  Invest New Drugs       Date:  2014-09-07       Impact factor: 3.850

8.  Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.

Authors:  Emilie P Buddingh; Marco W Schilham; S Eriaty N Ruslan; Dagmar Berghuis; Karoly Szuhai; Jolien Suurmond; Antonie H M Taminiau; Hans Gelderblom; R Maarten Egeler; Massimo Serra; Pancras C W Hogendoorn; Arjan C Lankester
Journal:  Cancer Immunol Immunother       Date:  2011-01-15       Impact factor: 6.968

9.  Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.

Authors:  Kazuhisa Sugiu; Hiroshi Tazawa; Joe Hasei; Yasuaki Yamakawa; Toshinori Omori; Tadashi Komatsubara; Yusuke Mochizuki; Hiroya Kondo; Shuhei Osaki; Tomohiro Fujiwara; Aki Yoshida; Toshiyuki Kunisada; Koji Ueda; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-10       Impact factor: 3.333

10.  Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research.

Authors:  Xian-biao Xie; Jun-qiang Yin; Li-li Wen; Zhen-hua Gao; Chang-ye Zou; Jin Wang; Gang Huang; Qing-lian Tang; Chiara Colombo; Wei-ling He; Qiang Jia; Jing-nan Shen
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.